No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MORF240719C50000
- 5.41
- -0.59-9.83%
15min DelayTrading Jul 9 09:45 ET
6.00High5.41Low
6.00Open6.00Pre Close4 Volume19 Open Interest50.00Strike Price2.34KTurnover0.00%IV-0.48%PremiumJul 19, 2024Expiry Date5.68Intrinsic Value100Multiplier10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma10.12Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Eli Lilly Strikes $3.2 Billion Deal to Acquire Morphic
Eli Lilly (LLY) will buy biopharmaceutical company Morphic (MORF) for roughly $3.2 billion in a bid to expand its immunology portfolio with oral therapies targeting cell proteins for chronic diseases.
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
A Quick Look at Today's Ratings for Morphic(MORF.US), With a Forecast Between $57 to $64
On Jul 09, major Wall Street analysts update their ratings for $Morphic(MORF.US)$, with price targets ranging from $57 to $64.Wells Fargo analyst Derek Archila maintains with a buy rating, and
Express News | RBC Capital Downgrades Morphic Holding to Sector Perform, Lowers Price Target to $57
Morphic Holding Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 1.42% RBC Capital $70 → $57 Downgrades Outperform → Sector Perform 03/08/2024 17.44%
TD Cowen Downgrades Morphic Holding to Hold From Buy
Morphic Holding (MORF) has an average rating of outperform and price targets ranging from $30 to $64, according to analysts polled by Capital IQ.Price: 55.80, Change: +0.06, Percent Change: +0.11
Comments
$MORF 240719 55.00C$ calls are destroyed for what? .007% change lol
$Eli Lilly and Co(LLY.US$ recent larger M&A: $Morphic(MORF.US$ , $PNT, $DICE, Versanis
Common theme: all bought post-POM, pre-POC / full de-risking. Higher clinical risk, offset by lower price
$LLY is uniquely positioned to employ such a strategy right now; admirable to see mgmt recognize & leverage that
Common theme: all bought post-POM, pre-POC / full de-risking. Higher clinical risk, offset by lower price
$LLY is uniquely positioned to employ such a strategy right now; admirable to see mgmt recognize & leverage that
1
Morning Movers
Gapping up
$Boeing(BA.US$ stock rose 0.90% after the aircraft manufacturer agreed to plead guilty to a criminal fraud conspiracy charge to resolve a U.S. Justice Department investigation into two 737 MAX fatal crashes and will pay a $243.6 million fine.
$Paramount Global-B(PARA.US$ stock rose 2.87% after Skydance Media agreed to acquire the entertainment giant, with the overall deal valued at over $8 billion....
Gapping up
$Boeing(BA.US$ stock rose 0.90% after the aircraft manufacturer agreed to plead guilty to a criminal fraud conspiracy charge to resolve a U.S. Justice Department investigation into two 737 MAX fatal crashes and will pay a $243.6 million fine.
$Paramount Global-B(PARA.US$ stock rose 2.87% after Skydance Media agreed to acquire the entertainment giant, with the overall deal valued at over $8 billion....
Expand 36
5
$Morphic(MORF.US$ soo very high
Read more